JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase III study to compare the preventive effect of recurrent brain infarction and safety of
Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic
acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Aspirin Aspirin, Dipyridamole Drug Combination Dipyridamole